Stock 688513 CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Chengdu Easton Biopharmaceuticals Co., Ltd.

Equities

688513

CNE100004397

End-of-day quote Shanghai S.E.
Other stock markets
 18:00:00 2024-05-27 EDT 		5-day change 1st Jan Change
56.24 CNY +0.43% Intraday chart for Chengdu Easton Biopharmaceuticals Co., Ltd. -1.75% -11.82%
05-22 China Gives Green Light for Easton Biopharma's Arterial Occlusive Disease Tablets MT
04-22 Chengdu Easton Biopharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
China Gives Green Light for Easton Biopharma's Arterial Occlusive Disease Tablets
MT
Chengdu Easton Biopharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Easton Biopharma's Unit Gets Nod to Market Bisoprolol Amlodipine Tablets
MT
Chengdu Easton Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Tranche Update on Chengdu Easton Biopharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on August 14, 2023.
CI
Chengdu Easton Registers Heart Failure Drug
MT
Chengdu Easton Biopharmaceuticals Co., Ltd.(XSSC:688513) dropped from S&P Global BMI Index
CI
Chengdu Easton Biopharma Registers Ibuprofen Injection For Premature Babies
MT
Chengdu Easton Biopharmaceuticals' Unit Gets US FDA's Nod for Nalmefene Hydrochloride Injection; Shares Rise 5%
MT
Chengdu Easton Biopharma Registers Hypertension Drug
MT
Chengdu Easton Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Chengdu Easton Biopharma Registers Blood Pressure Control Drug
MT
Chengdu Easton Biopharma's Antiepileptic Drug Gets Marketing Nod in China
MT
Tranche Update on Chengdu Easton Biopharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on August 14, 2023.
CI
Easton Biopharma Unit's Production Line Passes US FDA Inspection
MT
Chengdu Easton Biopharmaceuticals Co., Ltd.(XSSC:688513) added to S&P Global BMI Index
CI
Certain A Shares of Chengdu Easton Biopharmaceuticals Co., Ltd. are subject to a Lock-Up Agreement Ending on 2-SEP-2023.
CI
Chengdu Easton Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Chengdu Easton Biopharma to Repurchase Up to 200 Million Yuan Shares
MT
Chengdu Easton Biopharmaceuticals Co., Ltd. announces an Equity Buyback for CNY 200 million worth of its shares.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 688513 Stock
  4. News Chengdu Easton Biopharmaceuticals Co., Ltd.